Phathom Pharmaceuticals, Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending December 30, 2020 was $-205 Thousand (a -Infinity% decrease compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) decreased by -100.82%
  • Annual Repayment/Issuance of Debt (Net) for 2020 was $24.8 Million (a -78.1% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $113 Million (a 5859.21% increase from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending December 30, 2020 was $24.8 Million (a -0.82% decrease compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -82.06% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$24.8 Million $25 Million $25 Million $138 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of Phathom Pharmaceuticals, Inc.

Most recent Repayment/Issuance of Debt (Net)of PHAT including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.21 $0.0 $0.0 $25.0 $24.8
2019 $0.0 $0.0 $113.17 $113.23
2018 $1.05 $0.85 $1.9

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.